Coronary heart disease in patients with low LDL-cholesterol: Benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors

Circulation

Volumn 105, Issue 12, 2002, Pages 1424-1428

  Sacks, Frank M ^a   Tonkin, Andrew M ^a   Craven, Timothy ^a   Pfeffer, Marc A ^a   Shepherd, James ^a   Keech, Anthony ^a   Furberg, Curt D ^a   Braunwald, Eugene ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cholesterol; Coronary disease; Diabetes mellitus; Drugs; Lipoproteins

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SMOKING; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AUSTRALIA; CANADA; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETES COMPLICATIONS; DIABETES MELLITUS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; NEW ZEALAND; PRAVASTATIN; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UNITED STATES;

EID: 0037177205     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000012918.84068.43     Document Type: Article

References (11)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
5. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCaps
6. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) Project, a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and the West of Scotland Coronary Prevention Study (WOSCOPS)
7. Estimation of the concentration of LDL-C in plasma without use of the preparative ultracentrifuge
8. Plasma triglyceride level and mortality from coronary heart disease
9. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analysis in the CARE trial
10. Position statement: Management of dyslipidemia in adults with diabetes
11. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation treatment of high blood cholesterol in adults (Adult Treatment Panel III)